Fig. 3From: Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysisSubgroup analysis of sPD-L1 levels versus OS/PFS after different treatment durationsBack to article page